Last reviewed · How we verify

NCT04937192

SNP-based Prediction of Recurrence Risk in Kidney Stone Patients

Status unknown Last updated 25 October 2022
What this trial tests

trial testing No intervention in Kidney Stone in 1,300 participants. Status unknown.

Timeline
1 January 2012
Primary endpoint
31 December 2022
31 December 2023

Quick facts

Lead sponsorThe First Affiliated Hospital of Guangzhou Medical University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,300
Start date1 January 2012
Primary completion31 December 2022
Estimated completion31 December 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Who can join

18 and older, any sex, with Kidney Stone. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to gain new knowledge about genetic risk factors that may affect the kidney stone recurrence. The study seeks to understand if different forms of genes result in an increased risk of kidney stone recurrence.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Predictive value of single-nucleotide polymorphism signature for nephrolithiasis recurrence: a 5-year prospective study.
    Zhu W, Zhang X, Zhou Z, Sun Y, et al · · 2023 · cited 2× · PMID 37915892 · DOI 10.1093/ckj/sfad119

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Kidney Stone

Currently open trials in the same condition.

Other The First Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04937192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing